{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1076, 'offsetInEndSection': 1184, 'text': 'multiple sclerosis, AQP4-IgG-positive neuromyelitis optica spectrum disorder, and MOG-IgG-associated disorde', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31425702'}, {'offsetInBeginSection': 217, 'offsetInEndSection': 410, 'text': ' The antibody against aquaporin-4 (AQP4)-immunoglobulin G (IgG) discovered in 2004 was found to be both the pathologic cause and a reliable biomarker for neuromyelitis optica spectrum disorders', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31425702'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 145, 'text': 'Recently, several serum biomarkers have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34212756'}, {'offsetInBeginSection': 1468, 'offsetInEndSection': 1581, 'text': 'GFAP might be the most appropriate for monitoring NMOSD longitudinally, which warrants future confirming studies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34212756'}, {'offsetInBeginSection': 282, 'offsetInEndSection': 471, 'text': 'We prospectively recruited consecutive NMOSD patients with anti-aquaporin-4 antibody and obtained serum samples at enrollment, after 6-12\\u2009months of follow-up (main period), and at attacks. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34212756'}, {'offsetInBeginSection': 1084, 'offsetInEndSection': 1238, 'text': 'During the study, five (8%) patients developed new attacks; only serum GFAP levels increased consistently upon these events compared with baseline levels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34212756'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 294, 'text': 'Neuromyelitis optica (NMO) is an inflammatory disease that resembles MS in the relapsing clinical course of optic neuritis and myelitis. Two decades of studies have revealed that autoantibodies, reactive to the water channel protein aquaporin 4 (AQP4)\\xa0are detected in the core group of patients', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35635574'}, {'offsetInBeginSection': 2783, 'offsetInEndSection': 2947, 'text': 'During the acute phase of NMOSD and MOGAD, plasma C3 and C4 may become potential biomarkers for distinguishing the two diseases and reflecting the NMOSD BBB damage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35898513'}, {'offsetInBeginSection': 291, 'offsetInEndSection': 613, 'text': 'The discovery of the pathogenic aquaporin-4 (AQP4)-IgG autoantibody and characterization of NMOSD as an autoimmune astrocytopathy have spearheaded the identification of key immunologic therapeutic targets in this disease, including but not limited to the complement system, the interleukin 6 (IL-6) receptor, and B cells. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35938660'}, {'offsetInBeginSection': 1211, 'offsetInEndSection': 1478, 'text': '. As our understanding regarding the immune pathophysiology of NMOSD expands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP), may facilitate earlier relapse detection and inform long-term treatment decisions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35938660'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 276, 'text': 'We investigated the serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels in a cohort of Chinese patients with neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) in relation to clinical disease course and treatment.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34278578'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 90, 'text': 'Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33724534'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 648, 'text': 'OBJECTIVE: To test the hypothesis that serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), which are an intermediate astrocyte and neuron filaments, respectively, are clinically useful biomarkers of disease activity and disability in neuromyelitis optica spectrum disorders (NMOSD).METHODS: Levels of GFAP and NfL in serum (sGFAP and sNfL, respectively) and in CSF samples were measured in healthy controls (HCs) (n = 49; 49 serum samples), patients with NMOSD (n = 33; 42 CSF and 102 serum samples), and patients with multiple sclerosis (MS) (n = 49; 53 CSF and 91 serum samples) by ultrasensitive single-mo', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31471502'}]\n\n\n                 'What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"GFAP\", \"glial fibrillary acidic protein\", \"anti-aquaporin-4 antibody\", \"quaporin-4 (AQP4)-immunoglobulin G (IgG)\", \"Plasma C3\", \"Plasma C4\", \"serum neurofilament light chain\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 432, 'offsetInEndSection': 768, 'text': 'Due to several inflammatory changes that occur in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections such as alterations in the levels of clotting factors, platelet activation leads to thrombus formation in coronary and cerebral vessels, leading to myocardial infarction and cerebrovascular accidents, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34083499'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 126, 'text': 'A prothrombotic state is reported with severe COVID-19 infection, which can manifest in venous and arterial thrombotic events.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33586113'}, {'offsetInBeginSection': 1008, 'offsetInEndSection': 1287, 'text': ' In 28 studies including 2928 patients, thrombotic complications occurred in 34% of ICU-managed patients, with deep venous thrombosis reported in 16.1% and pulmonary embolism in 12.6% of patients, despite anticoagulant thromboprophylaxis, and were associated with high mortality.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33586113'}, {'offsetInBeginSection': 1512, 'offsetInEndSection': 1636, 'text': 'Despite thromboprophylaxis, there is a very high incidence of thrombotic complications in patients with COVID-19 on the ICU.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33586113'}, {'offsetInBeginSection': 14, 'offsetInEndSection': 326, 'text': 'Emerging evidence points to an association between severe clinical presentation of COVID-19 and increased risk of thromboembolism. One-third of patients hospitalized due to severe COVID-19 develops macrovascular thrombotic complications, including venous thromboembolism, myocardial injury/infarction and stroke.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33074525'}, {'offsetInBeginSection': 80, 'offsetInEndSection': 214, 'text': 'Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32492712'}, {'offsetInBeginSection': 730, 'offsetInEndSection': 1151, 'text': 'The radiographically confirmed VTE rate was 4.8% (95% confidence interval [CI], 2.9-7.3), and the overall thrombotic complication rate was 9.5% (95% CI, 6.8-12.8). The overall and major bleeding rates were 4.8% (95% CI, 2.9-7.3) and 2.3% (95% CI, 1.0-4.2), respectively. In the critically ill, radiographically confirmed VTE and major bleeding rates were 7.6% (95% CI, 3.9-13.3) and 5.6% (95% CI, 2.4-10.7), respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32492712'}, {'offsetInBeginSection': 734, 'offsetInEndSection': 857, 'text': 'Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32367170'}, {'offsetInBeginSection': 1129, 'offsetInEndSection': 1189, 'text': 'No patient developed disseminated intravascular coagulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32367170'}, {'offsetInBeginSection': 1631, 'offsetInEndSection': 1766, 'text': 'Despite anticoagulation, a high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32367170'}, {'offsetInBeginSection': 117, 'offsetInEndSection': 363, 'text': 'Critically ill COVID patients are at increased risk of serious thrombotic events and hence increased mortality. On the other side, COVID-19 patients are also showing major life-threatening bleeds, especially when systemic anticoagulation is used.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34047936'}, {'offsetInBeginSection': 816, 'offsetInEndSection': 1035, 'text': 'Major bleeding occurred in six of the 25 studied patients. Four patients were on therapeutic anticoagulation at the onset of the bleed, two required embolization for bleeding control and one died from hemorrhagic shock.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34047936'}, {'offsetInBeginSection': 1784, 'offsetInEndSection': 2091, 'text': 'Our analysis does not suggest that rates of intracerebral hemorrhage are higher in patients with COVID-19. The higher mortality in patients with intracerebral hemorrhage and COVID-19 compared with those without COVID-19 is likely mediated by higher frequency of comorbidities and adverse in-hospital events.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34231186'}, {'offsetInBeginSection': 799, 'offsetInEndSection': 1159, 'text': 'However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32586214'}, {'offsetInBeginSection': 178, 'offsetInEndSection': 403, 'text': 'Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32586214'}, {'offsetInBeginSection': 571, 'offsetInEndSection': 904, 'text': 'The most common thrombotic complication is pulmonary embolism, which though may occur in the absence of a recognizable deep venous thrombosis and may be due to pulmonary arterial thrombosis rather than embolism, resulting in thrombotic occlusion of small- to mid-sized pulmonary arteries and subsequent infarction of lung parenchyma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32924567'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 330, 'text': 'A large proportion of patients with coronavirus disease 19 (COVID-19) suffer from excessive coagulation activation and coagulopathy which predisposes them to a wide spectrum of thrombotic events including in situ pulmonary thrombosis, deep-vein thrombosis, and associated pulmonary embolism, as well as arterial thrombotic events.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35957796'}, {'offsetInBeginSection': 94, 'offsetInEndSection': 300, 'text': 'These include microvascular and macrovascular thrombotic complications such as arterial and venous thromboembolism, myocardial injury or inflammation resulting in infarction, heart failure, and arrhythmias.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35967591'}, {'offsetInBeginSection': 170, 'offsetInEndSection': 294, 'text': 'Several observational studies have described hemostatic derangements and thrombotic complications in patients with COVID-19.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35643053'}, {'offsetInBeginSection': 89, 'offsetInEndSection': 216, 'text': 'Most of these complications are associated with venous thromboembolism and pulmonary embolism; and arterial thrombosis is rare.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34271813'}, {'offsetInBeginSection': 129, 'offsetInEndSection': 343, 'text': 'Most of the reports on a high incidence of thrombotic complications are in relation to deep vein thrombosis and pulmonary embolism, while the evidence about arterial thrombosis in patients with COVID-19 is limited.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32474145'}, {'offsetInBeginSection': 301, 'offsetInEndSection': 506, 'text': 'Common thrombotic complications include pulmonary embolism, cerebral infarction, or venous thromboembolism; less commonly seen are acute myocardial injury, renal artery thrombosis, and mesenteric ischemia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33296828'}, {'offsetInBeginSection': 14, 'offsetInEndSection': 175, 'text': 'COVID-19 may predispose to both venous and arterial thromboembolism due to excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32291094'}, {'offsetInBeginSection': 409, 'offsetInEndSection': 805, 'text': 'Thrombotic complications from COVID-19 are believed to be due to a hyperinflammatory response caused by the virus. Several complications have been described in the literature. These include acute limb ischemia, abdominal and thoracic aortic thrombosis, mesenteric ischemia, myocardial infarction, venous thromboembolism, acute cerebrovascular accident, and disseminated intravascular coagulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33036855'}]\n\n\n                 'What are the major thrombotic complications in patients with COVID-19?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Deep venous thrombosis\", \"DVT\", \"Deep vein thrombosis\", \"venous thrombosis\", \"Pulmonary embolism\", \"PE\", \"Venous thromboembolism\", \"venous thromboembolism (VTE)\", \"Stroke\", \"Cerebrovascular accident\", \"CVA\", \"Myocardial infarction\", \"MI\", \"myocardial injury/infarction\", \"acute myocardial infarction\", \"disseminated intravascular coagulation\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 527, 'text': 'Histone lysine and arginine residues are subject to a wide array of post-translational modifications including methylation, citrullination, acetylation, ubiquitination, and sumoylation. The combinatorial action of these modifications regulates critical DNA processes including replication, repair, and transcription. In addition, enzymes that modify histone lysine and arginine residues have been correlated with a variety of human diseases including arthritis, cancer, heart disease, diabetes, and neurodegenerative disorders.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18603028'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': 'Histone methylation represents one of the most critical epigenetic events in DNA function regulation in eukaryotic organisms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22777714'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 202, 'text': 'Studies into posttranslational modifications of histones, notably acetylation, have yielded important insights into the dynamic nature of chromatin structure and its fundamental role in gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10611321'}, {'offsetInBeginSection': 621, 'offsetInEndSection': 823, 'text': 'Microsequence analyses of H3 from Tetrahymena, yeast, and HeLa cells indicate that lysine 4 is a highly conserved site of methylation, which to date, is the major site detected in Tetrahymena and yeast.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10611321'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': 'Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10611321'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 590, 'text': 'Chromatin remodelling events play an important role in the secondary metabolism of filamentous fungi. Previously, we showed that a bacterium, Streptomyces rapamycinicus, is able to reprogram the histone-modifying Spt-Ada-Gcn5-acetyltransferase/ADA (SAGA/ADA) complex of the model fungus Aspergillus nidulans. Consequently, the histone H3 amino acids lysine 9 and lysine 14 at distinct secondary metabolism genes were specifically acetylated during the bacterial fungal interaction, which, furthermore, was associated with the activation of the otherwise silent orsellinic acid gene cluster.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23892751'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 425, 'text': \"Over the past year or so, methylation of histones has come to be recognised as a major player in the regulation of gene activity. This notion follows the discovery of lysine and arginine methyltransferases and proteins that recognise the methyl-lysine 'mark' on histones. Methylated histones have been implicated in heterochromatic repression, promoter regulation and the propagation of a repressed state via DNA methylation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11893494'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 276, 'text': 'Histones are the major protein constituent of chromatin in the eukaryotic nucleus. These proteins undergo a host of different post-translational modifications, including phosphorylation, acetylation, and methylation, which have profound effects on the remodeling of chromatin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15248813'}, {'offsetInBeginSection': 434, 'offsetInEndSection': 789, 'text': 'Recent studies have focused on histone arginine and lysine methylation and the roles of these modifications in transcriptional regulation and the establishment of heterochromatin. Concomitantly, several families of histone methyltransferases (HMTs) have been identified that catalyze the methylation of specific arginines or lysines in histones H3 and H4.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15248813'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 227, 'text': 'Histone modifications; acetylation, methylation (both Lysine and Arginine) etc., at different positions regulates the chromatin fluidity and function in a combinatorial manner, which could be referred as an epigenetic language.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22923743'}, {'offsetInBeginSection': 105, 'offsetInEndSection': 275, 'text': 'Histone acetylation is commonly associated with activation of gene expression whereas histone methylation is linked to either activation or repression of gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30466474'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 89, 'text': 'Lysine residue 9 of histone H3 can either be acetylated or mono-, di-, or tri-methylated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20054610'}, {'offsetInBeginSection': 149, 'offsetInEndSection': 303, 'text': 'Histone lysine methylation is known to either activate or repress gene expression depending upon the position and status of the methylated lysine residue.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19829087'}, {'offsetInBeginSection': 132, 'offsetInEndSection': 349, 'text': 'Histone lysine methylation has been implicated in both gene activation and repression, depending on the specific lysine (K) residue that becomes methylated and the state of methylation (mono-, di-, or trimethylation).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18003914'}, {'offsetInBeginSection': 464, 'offsetInEndSection': 602, 'text': 'Kinetic studies show that acetylation at any of the four acetylatable lysine residues of histone H4 results in more efficient methylation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19358899'}, {'offsetInBeginSection': 236, 'offsetInEndSection': 443, 'text': ' Histone methylation modification affects chromatin through the addition of methyl groups to lysine or arginine residues of histones H3 and H4 by means of histone methyl transferases or histone demethylases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32762486'}, {'offsetInBeginSection': 214, 'offsetInEndSection': 396, 'text': \"The most well studied posttranslational modification of histones is the acetylation of epsilon-amino groups on conserved lysine residues in the histones' amino-terminal tail domains.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10825229'}, {'offsetInBeginSection': 155, 'offsetInEndSection': 363, 'text': 'Among the well-known covalent modifications of histones, the reversible acetylation of internal lysine residues in histone amino-terminal domains has long been positively linked to transcriptional activation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11395403'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 65, 'text': 'Chemical mechanisms of histone lysine and arginine modifications.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18603028'}, {'offsetInBeginSection': 414, 'offsetInEndSection': 597, 'text': 'Histone methylation events, especially on arginine- and lysine-residues, are among the best-characterized PTMs, and many of these modifications have been linked to downstream effects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22122749'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 320, 'text': 'Histone post-translational modifications are essential for the regulation of gene expression in eukaryotes. Gcn5 (KAT2A) is a histone acetyltransferase that catalyzes the post-translational modification at multiple positions of histone H3 through the transfer of acetyl groups to the free amino group of lysine residues.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32890768'}]\n\n\n                 'When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Lysine\", \"lysine residues\", \"Arginine\", \"arginine residues\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 12, 'offsetInEndSection': 134, 'text': 'Hepcidin, a key regulator of iron homeostasis, is increased by iron overload and inflammation while suppressed by hypoxia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24739829'}, {'offsetInBeginSection': 248, 'offsetInEndSection': 345, 'text': 'Hepcidin, discovered in the year 2000, is an endogenous peptide responsible for iron homeostasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23986220'}, {'offsetInBeginSection': 346, 'offsetInEndSection': 470, 'text': 'Recent data suggests that hepcidin is a major mediator of anemia and plays a central role in iron homeostasis and metabolism', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23986220'}, {'offsetInBeginSection': 990, 'offsetInEndSection': 1296, 'text': 'The regulation of iron export is controlled predominantly at the systemic level by the master regulator of iron homeostasis hepcidin. Hepcidin, in turn, responds to changes in body iron demand, making use of a range of regulatory mechanisms that center on the bone morphogenetic protein signaling pathway. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24132807'}, {'offsetInBeginSection': 143, 'offsetInEndSection': 383, 'text': 'In mammalian systems, iron availability is controlled by the interaction of the iron-regulatory hormone hepcidin with ferroportin, a molecule that functions both as the hepcidin receptor as well as the sole known cellular exporter of iron. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31723763'}, {'offsetInBeginSection': 384, 'offsetInEndSection': 534, 'text': 'y reducing iron export through ferroportin to blood plasma, hepcidin inhibits the mobilization of iron from stores and the absorption of dietary iron.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31723763'}, {'offsetInBeginSection': 80, 'offsetInEndSection': 405, 'text': 'Information on the metabolism of hepcidin and its possible significance as a biochemical parameter in iron deficiency anemia is reported in this review, which was based on a survey of the databases PubMed and LILACS for articles published between 2006 and 2010 on hepcidin as a biomarker for the regulation of iron metabolism', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21152835'}, {'offsetInBeginSection': 13, 'offsetInEndSection': 134, 'text': 'Hepcidin is related to the pathogenesis of chronic renal failure anemia, which is considered a chronic inflammatory state', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32720970'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 66, 'text': 'Iron transport across the human placenta is regulated by hepcidin.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33069164'}, {'offsetInBeginSection': 339, 'offsetInEndSection': 473, 'text': 'we investigate the role of hepcidin, a master regulator of iron homeostasis, on regulation of iron transport across trophoblast cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33069164'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 76, 'text': 'The hepatic hormone hepcidin is a key regulator of systemic iron metabolism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24385536'}, {'offsetInBeginSection': 655, 'offsetInEndSection': 907, 'text': 'Although hepcidin, a small circulating peptide produced by the liver, has been found to be the key regulator of iron trafficking, molecular pathways of iron sensing that control iron metabolism and hepcidin production are still incompletely understood.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22968710'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 132, 'text': 'Hepcidin is a liver-made peptide proposed to be a central regulator of intestinal iron absorption and iron recycling by macrophages.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12433676'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 187, 'text': 'The peptide hormone hepcidin is a key homeostatic regulator of iron metabolism and involved in pathological regulation of iron in response to infection, inflammation, hypoxia, and anemia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21439478'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 127, 'text': 'The peptide hormone hepcidin is one of the key regulators of iron absorption, plasma iron levels, and tissue iron distribution.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33567510'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'Hepcidin is an iron-regulatory protein that is upregulated in response to increased iron or inflammatory stimuli.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17593032'}, {'offsetInBeginSection': 113, 'offsetInEndSection': 230, 'text': 'Hepcidin, a small peptide synthesized in the liver, is a key regulator of iron absorption and homeostasis in mammals.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17557118'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 158, 'text': 'Hepcidin, a 25-amino-acid peptide secreted by the liver, distributed in the plasma and excreted in urine, is a key central regulator of body iron homeostasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21073997'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 84, 'text': 'Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12663437'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 210, 'text': 'Hepcidin is a small disulfide-rich peptide hormone that plays a key role in the regulation of iron homeostasis by binding and mediating the degradation of the cell membrane iron efflux transporter, ferroportin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22776295'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 90, 'text': 'Hepcidin is a key hormone that is involved in the control of iron homeostasis in the body.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23722909'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 153, 'text': 'PURPOSE OF REVIEW: Hepcidin is a recently discovered hepatic peptide that regulates intestinal iron absorption as well as maternal-fetal iron transport a', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15314524'}, {'offsetInBeginSection': 291, 'offsetInEndSection': 725, 'text': 'n from hemoglobin. Connecting iron metabolism to innate immunity, hepcidin is a key mediator of hypoferremia of inflammation.RECENT FINDINGS: The essential role of hepcidin in iron metabolism is being elucidated through mouse and human genetics, biochemistry, and cell biology.SUMMARY: Studies of hepcidin are leading to fundamental understanding of iron homeostasis and pointing to potential treatments for hemochromatosis and anemia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15314524'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 73, 'text': 'The role of hepcidin in regulating iron homeostasis in selected diseases.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31280251'}, {'offsetInBeginSection': 100, 'offsetInEndSection': 154, 'text': ' Hepcidin is a key regulator of systemic iron balance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27905193'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 62, 'text': 'The Dual Role of Hepcidin in Brain Iron Load and Inflammation.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30374287'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 52, 'text': 'Hepcidin is the master regulator of iron metabolism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30530987'}, {'offsetInBeginSection': 139, 'offsetInEndSection': 219, 'text': ' Studies suggest a dual role of hepcidin in neuronal iron load and inflammation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30374287'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'Hepcidin is a key regulator controlling iron intestinal absorption and distribution through the body.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21142632'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 49, 'text': 'Hepcidin is the key regulator of iron metabolism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19839848'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 59, 'text': 'Hepcidin is the key regulator of systemic iron homeostasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17768112'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 61, 'text': 'Hepcidin: a direct link between iron metabolism and immunity.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16009323'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 34, 'text': 'Hepcidin: A key regulator of iron.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31431773'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 106, 'text': 'Hepcidin, a key regulator of iron homeostasis, is known to have three isoforms: hepcidin-20, -22, and -25.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21136948'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 116, 'text': 'Hepcidin, a key regulator of iron metabolism, plays a crucial role in the pathogenesis of anemia of chronic disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19681654'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 90, 'text': 'Hepcidin, which is mainly produced by the liver, is the key regulator in iron homeostasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24293278'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 126, 'text': 'Hepcidin is the key regulator of iron absorption and recycling, and its expression is suppressed by red blood cell production.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25782630'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'Hepcidin, a key regulator of iron metabolism, decreases intestinal absorption of iron and its release from macrophages.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16497104'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 115, 'text': 'Hepcidin is a key regulator of iron homeostasis and plays a role in the pathogenesis of anaemia of chronic disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25852110'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Hepcidin is the master regulator of iron metabolism. It plays a key role in the regulation of iron transport across the duodenal epithelium, which in ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30530987'}, {'offsetInBeginSection': 223, 'offsetInEndSection': 373, 'text': 'ved in postmenopausal osteoporosis. Hepcidin is a key regulator of iron homeostasis. However, the exact role of hepcidin in bone metabolism and the un', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33820875'}, {'offsetInBeginSection': 70, 'offsetInEndSection': 220, 'text': 'central role in hepcidin regulation. Hepcidin is a key regulator ofiron homeostasis and has now been suggested as a central mediator ofiron metabolism', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24356737'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'BACKGROUND: Hepcidin is a central regulator of iron metabolism. Serum hepcidin levels are increased in patients with renal insufficiency, which may co', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23531037'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'BACKGROUND: Hepcidin is a key regulator of iron metabolism. It binds to ferroportin and causes the trapping of iron in cells, rendering it unavailable', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23807042'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 128, 'text': 'Hepcidin is a key regulator of iron homeostasis, while hemojuvelin is an important component of the hepcidin regulation pathway.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19249912'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 116, 'text': 'Hepatic peptide hormone hepcidin is the key regulator of iron metabolism and the mediator of anemia of inflammation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15886319'}, {'offsetInBeginSection': 126, 'offsetInEndSection': 218, 'text': 'Hepcidin is thought to be a key regulator in iron metabolism and has been implicated in ACD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16198622'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'The discovery of hepcidin as a key regulator of iron homeostasis has advanced our current knowledge of this field.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18936232'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Hepcidin, a key regulator of iron metabolism, is synthesized by the liver. Hepcidin binds to the iron exporter ferroportin to regulate the release of ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15797999'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 186, 'text': 'Hepcidin is a main regulator of iron metabolism, of which abnormal expression affects intestinal absorption and reticuloendothelial sequestration of iron by interacting with ferroportin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30798808'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 139, 'text': 'Hepcidin is the major regulator of systemic iron metabolism, while the role of this peptide in the brain has just recently been elucidated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30374287'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 52, 'text': 'Regulation of the Iron Homeostatic Hormone Hepcidin.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28096133'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 250, 'text': 'The serum level of iron in humans is tightly controlled by the action of the hormone hepcidin on the iron efflux transporter ferroportin. Hepcidin regulates iron absorption and recycling by inducing the internalization and degradation of ferroportin1', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32814342'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 387, 'text': 'Since its discovery in 2001, there have been a number of important discoveries and findings that have increased our knowledge about the functioning of hepcidin. Hepcidin, the master iron regulator has been shown to be regulated by a number of physiological stimuli and their associated signaling pathways. This chapter will summarize our current understanding of how these physiological ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30798816'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 214, 'text': 'Iron is an essential metal for cell survival that is regulated by the peptide hormone hepcidin. However, its influence on certain diseases is directly related to iron metabolism or secondary to underlying diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28514781'}]\n\n\n                 'Hepcidin is a key regulator of what processes?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"iron homeostasis\", \"iron metabolism\", \"iron transport\", \"inflammation\", \"anemia\", \"hypoxia\", \"bone morphogenetic protein signaling pathway\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 189, 'text': 'Cat-eye syndrome is a rare genetic disease that involves the proximal long (q) arm of chromosome 22. The classic clinical triad includes coloboma of the iris, ears, and anal malformations. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35911297'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 299, 'text': 'BACKGROUND: Cat eye syndrome (CES) is a rare chromosomal disease, with estimated incidence of about 1 in 100,000 live newborns. The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities is present in 40% of patients, and other congenital defects may also be observed. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36076277'}]\n\n\n                 'What is the triad of the Cat eye syndrome?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"coloboma of the iris\", \"auricular abnormalities\", \"anal malformation\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 475, 'offsetInEndSection': 881, 'text': 'Furthermore, 218 p53-bound enhancers (Enhp53) were identified by analyzing p53 ChIP-seq in HepG2 cells after DNA damage. The results showed that the enhancer expression and histone markers of enhancers (H3K4me1, H3K4me2, H3K4me3, H3K9ac, and H3K27ac) revealed significantly higher level on Enhp53 than Enhno-p53 which suggested that p53 participated in regulating enhancer activity and chromatin structure.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32695760'}, {'offsetInBeginSection': 511, 'offsetInEndSection': 758, 'text': 'In general, transcription start sites of actively transcribed genes are marked by trimethylated H3K4 (H3K4me3) and acetylated H3K27 (H3K27ac), and active enhancers can be identified by enrichments of both monomethylated H3K4 (H3K4me1) and H3K27ac.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23739122'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 385, 'text': 'DNA methylation at promoters is largely correlated with inhibition of gene expression. However, the role of DNA methylation at enhancers is not fully understood, although a crosstalk with chromatin marks is expected. Actually, there exist contradictory reports about positive and negative correlations between DNA methylation and H3K4me1, a chromatin hallmark of enhancers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29233090'}, {'offsetInBeginSection': 624, 'offsetInEndSection': 1389, 'text': 'We hypothesized \"seesaw\" dynamics between H3K4me1 and H3K4me3 in the low and intermediate DNA methylation range, in which DNA methylation discriminates between enhancers and promoters, marked by H3K4me1 and H3K4me3, respectively. Low methylated regions are H3K4me3 enriched, while those with intermediate DNA methylation levels are progressively H3K4me1 enriched. Additionally, the enrichment of H3K27ac, distinguishing active from primed enhancers, follows a plateau in the lower range of the intermediate DNA methylation level, corresponding to active enhancers, and decreases linearly in the higher range of the intermediate DNA methylation. Thus, the decrease of the DNA methylation switches smoothly the state of the enhancers from a primed to an active state.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29233090'}, {'offsetInBeginSection': 237, 'offsetInEndSection': 461, 'text': 'For example, although histone H3 lysine 4 mono-methylation (H3K4me1) indicates the presence of transcriptional gene enhancers, it does not provide clearcut information about their actual position and stage-specific activity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21847099'}, {'offsetInBeginSection': 261, 'offsetInEndSection': 513, 'text': 'Studies performed on mammalian embryonic stem cells and Drosophila embryos suggest that active enhancers form part of a defined chromatin landscape marked by histone H3 lysine 4 mono-methylation (H3K4me1) and histone H3 lysine 27 acetylation (H3K27ac).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22593555'}, {'offsetInBeginSection': 112, 'offsetInEndSection': 265, 'text': 'In mammalian cells, active or primed enhancers are commonly marked by monomethylation of histone H3 at lysine 4 (H3K4me1) in a cell-type-specific manner.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29255264'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 74, 'text': 'H3K4 tri-methylation provides an epigenetic signature of active enhancers.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21847099'}, {'offsetInBeginSection': 79, 'offsetInEndSection': 286, 'text': 'Although certain chromatin features, such as the histone acetyltransferase P300 and the histone modification H3K4me1, indicate the presence of enhancers, only a fraction of enhancers are functionally active.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24038352'}, {'offsetInBeginSection': 452, 'offsetInEndSection': 681, 'text': 'The coexistence of high mono-methylation and low tri-methylation levels of lysine 4 of histone H3 is considered a signature of enhancers, but a comprehensive view of histone modifications associated to enhancers is still lacking.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28981749'}, {'offsetInBeginSection': 421, 'offsetInEndSection': 776, 'text': 'Here we use ChIP sequencing (ChIP-seq) to identify domains enriched for the histone marks histone H3 lysine 4 trimethylation, histone H3 lysine 4 monomethylation, and histone H3 lysine 27 acetylation (H3K4me3, H3K4me1, and H3K27ac) and define, for the first time, the super enhancers and typical enhancers active in primary human corneal epithelial cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28916725'}, {'offsetInBeginSection': 718, 'offsetInEndSection': 842, 'text': 'We find that histone H3K27ac distinguishes active enhancers from inactive/poised enhancer elements containing H3K4me1 alone.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21106759'}, {'offsetInBeginSection': 345, 'offsetInEndSection': 517, 'text': 'These complex regulatory mechanisms are often defined by combinatorial histone PTMs; for instance, active enhancers are commonly occupied by both marks H3K4me1 and H3K27ac.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28649883'}, {'offsetInBeginSection': 586, 'offsetInEndSection': 744, 'text': 'Using ChIP-Seq data, we examined these regions for presence of H3K4me1, H3K27ac, and H3K9ac histone marks (typically associated with latent/active enhancers).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34134708'}]\n\n\n                 'What histone marks are indicative of enhancers in the chromatin landscape of a given cell?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"H3K4me1\", \"H3K4me1-enriched\", \"H3K27Ac\", \"acetylated H3K27\", \"H3K4me3\", \"H3K4me3-enriched\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 343, 'offsetInEndSection': 616, 'text': 'sensitization, behavioral changes, and low body mass index (BMI). One possible cellular target that may mediate some of these findings is the hypocretin/orexin neurons. This neuronal system plays a role in regulating wakefulness/sleep cycles, pain perception, and appetite.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34279849'}, {'offsetInBeginSection': 463, 'offsetInEndSection': 582, 'text': ' Food intake, in contrast, receives circadian modulation through hormones such as leptin, ghrelin, insulin and orexin. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34228879'}, {'offsetInBeginSection': 153, 'offsetInEndSection': 412, 'text': 'A low level of hypocretin-1/orexin-A in the cerebrospinal fluid is sufficient to diagnose narcolepsy type 1, being a highly specific and sensitive biomarker, and the irreversible loss of hypocretin neurons is responsible for the main symptoms of the disease: ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35624073'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 138, 'text': 'Orexins, or hypocretins, are excitatory neuropeptides involved in the regulation of feeding behavior and the sleep and wakefulness states.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35886210'}, {'offsetInBeginSection': 328, 'offsetInEndSection': 628, 'text': \"n the present review, we firstly describe the mechanisms underlining the orexin system and their interactions with the central nervous system (CNS). Then, the system's involvement in goal-directed behaviors, sleep/wakefulness state regulation, feeding behavior and energy homeostasis, reward system, \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35886210'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 200, 'text': 'The effects of orexinergic peptides are diverse and are mediated by orexin-1 and orexin-2 receptors. Antagonists that target both receptors have been shown to promote sleep initiation and maintenance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34628482'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 211, 'text': 'UNLABELLED: Orexins (hypocretins) are neuropeptides that regulate multiple homeostatic processes, including reward and arousal, in part by exciting serotonergic dorsal raphe neurons, the major source of forebrai', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27683906'}, {'offsetInBeginSection': 1391, 'offsetInEndSection': 1580, 'text': 'This review discusses the mechanism by which orexins maintain sleep/wakefulness states and how this mechanism relates to other systems that regulate emotion, reward, and energy homeostasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23508038'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Central orexin/hypocretin neurons promote wakefulness, feeding and reward-seeking, and control blood glucose levels by regulating sympathetic outflow to the periphery.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22005675'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 77, 'text': 'Coordination of metabolism, arousal, and reward by orexin/hypocretin neurons.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32804153'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 76, 'text': 'Orexin/Hypocretin and MCH Neurons: Cognitive and Motor Roles Beyond Arousal.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33828450'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 82, 'text': 'Hypocretin/orexin neurons regulate many behavioral functions, including addiction.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26322330'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 80, 'text': 'Orexin (hypocretin) appears to play a role in the regulation of energy balances.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10624957'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 138, 'text': 'Orexin neurons (hypocretin neurons) have a critical role in the regulation of sleep/wakefulness, especially in the maintenance of arousal.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20861370'}, {'offsetInBeginSection': 303, 'offsetInEndSection': 490, 'text': 'Orexin neurons are \"multi-tasking\" neurons regulating a set of vital body functions, including sleep/wake states, feeding behavior, energy homeostasis, reward systems, cognition and mood.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28620314'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 429, 'text': 'The orexin-producing neurons in the lateral hypothalamus play an essential role in promoting arousal and maintaining wakefulness. These neurons receive a broad variety of signals related to environmental, physiological and emotional stimuli; they project to almost every brain region involved in the regulation of wakefulness; and they fire most strongly during active wakefulness, high motor activation, and sustained attention.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23683477'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 434, 'text': 'Orexins (synonymous with hypocretins) are recently discovered neuropeptides made exclusively in hypothalamus. Behavioral, anatomical, and neurophysiological studies show that a subset of these cells, specifically those in lateral hypothalamus (LH), are involved in reward processing and addictive behaviors. Fos expression in LH orexin neurons varied in proportion to conditioned place preference (CPP) for morphine, cocaine, or food.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19815001'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 306, 'text': 'Orexin A (OXA) and orexin B (OXB) are recently discovered neuropeptides that appear to play a role in various distinct functions such as arousal and the sleep-wake cycle as well as on appetite and regulation of feeding and energy homeostasis. Orexins were first described as neuropeptides expressed by a sp', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20353399'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 195, 'text': 'Orexin/hypocretin neurons located in the lateral hypothalamus play a critical role in the maintenance of arousal and contribute to the regulation of multiple homeostatic and behavioral processes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32804153'}]\n\n\n                 'What processes do orexin/hypocretin neurons regulate?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"sleep\", \"appetite\", \"wakefullness\", \"pain\", \"reward\", \"energy homeostasis\", \"goal-directed behaviors\", \"Arousal\", \"addiction\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 122, 'text': 'FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28835513'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 714, 'text': 'On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] \u226550%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS \u22651%), with disease progression on or after platinum-containing chemotherapy. P', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28835513'}]\n\n\n                 'What was Keytruda originally approved for by the FDA?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"irst-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] \\u226550%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations\", \"treatment of patients with mNSCLC whose tumors express PD-L1 (TPS \\u22651%), with disease progression on or after platinum-containing chemotherapy\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 868, 'offsetInEndSection': 1346, 'text': 'Independent factors associated with survival were previous HCC treatment (HR 2.01, 95% CI 1.23-3.27, p\\u2009=\\u20090.005), bi-lobar disease (HR 2.25, 95% CI 1.30-3.89, p\\u2009=\\u20090.003), ascites (HR 1.77, 95% CI 0.99-3.13, p\\u2009=\\u20090.05), neutrophil-to-lymphocyte ratio (HR 1.11, 95% CI 1.02-1.20, p\\u2009=\\u20090.01), Albumin-Bilirubin (ALBI) grade-3 (HR 2.69, 95% CI 1.22-5.92, p\\u2009=\\u20090.01), tumor thrombus (HR 2.95, 95% CI 1.65-5.24, p\\u2009<\\u20090.001), and disease control rate (HR 0.62, 95% CI 0.39-0.96, p\\u2009=\\u20090.03). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32281043'}, {'offsetInBeginSection': 306, 'offsetInEndSection': 448, 'text': 'We used each database to evaluate the relationship between the albumin-bilirubin grade (ALBI) and the microbiome in patients with hepatitis C.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32744764'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Association between the albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data-mining analysis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34534392'}, {'offsetInBeginSection': 405, 'offsetInEndSection': 495, 'text': 'At the diagnosis of PoPH, liver function was evaluated by albumin-bilirubin (ALBI) score. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34534392'}, {'offsetInBeginSection': 455, 'offsetInEndSection': 589, 'text': 'RESULTS: Fourteen, 13, and 24 patients were classified based on modified albumin-bilirubin (mALBI) grade 1, 2a, and 2b, respectively. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34534398'}]\n\n\n                 'Which variables are included in the ALBI grade?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"albumin\", \"bilirubin\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 126, 'offsetInEndSection': 407, 'text': 's FIP is an immune-mediated disease, treatment is mainly aimed at controlling the immune response triggered by the infection with the feline coronavirus (FCoV). Immune suppressive drugs such as prednisone or cyclophosphamide may slow disease progression but do not produce a cure. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18395801'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 178, 'text': 'A total of 12 clinically ill cats previously diagnosed as feline infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15123155'}, {'offsetInBeginSection': 109, 'offsetInEndSection': 236, 'text': 'YPOTHESIS: Feline interferon-omega (FeIFN-omega) prolongs survival time and increases quality of life in cats with FIP.ANIMALS:', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18196725'}, {'offsetInBeginSection': 615, 'offsetInEndSection': 730, 'text': 'All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18196725'}, {'offsetInBeginSection': 125, 'offsetInEndSection': 261, 'text': 'Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival time in cats with FIP, and increase their quality of life.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22092616'}, {'offsetInBeginSection': 1423, 'offsetInEndSection': 1535, 'text': 'Therefore, PPF does not appear to be an effective treatment option in cats with a late stage of the disease FIP.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22092616'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 393, 'text': 'Feline infectious peritonitis (FIP) is considered a fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive and well 2 years after diagnosis. The third cat survived 14 months but was treated for only 4.5 months. Further studies are necessary to assess the potential of the Polyprenyl Immunostimulant.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19482534'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 122, 'text': 'Effect of Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritoniti', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19482534'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 310, 'text': 'Feline infectious peritonitis (FIP) is a highly fatal disease caused by a virulent feline coronavirus in domestic and wild cats. We have previously reported the synthesis of potent coronavirus 3C-like protease (3CLpro) inhibitors and the efficacy of a protease inhibitor, GC376, in client-owned cats with FIP. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31585653'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 110, 'text': 'Combination siRNA therapy against feline coronavirus can delay the emergence of antiviral resistance in vitro.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25596968'}, {'offsetInBeginSection': 1780, 'offsetInEndSection': 1867, 'text': 'these data inform the potential therapeutic application of antiviral RNAi against FIPV.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25596968'}, {'offsetInBeginSection': 291, 'offsetInEndSection': 474, 'text': 'We previously reported the successful in vitro inhibition of FIPV replication by synthetic siRNA mediated RNA interference (RNAi) in an immortalised cell line (McDonagh et al., 2011).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25596968'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 108, 'text': 'Differential effects of viroporin inhibitors against feline infectious peritonitis virus serotypes I and II.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25701212'}, {'offsetInBeginSection': 546, 'offsetInEndSection': 643, 'text': ' However, it is not clear whether HMA and other viroporin inhibitors affect replication of FIPV. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25701212'}, {'offsetInBeginSection': 644, 'offsetInEndSection': 1010, 'text': \"e examined the effect of HMA and other viroporin inhibitors (DIDS [4,4'-disothiocyano-2,2'-stilbenedisulphonic acid] and amantadine) on infection by FIPV serotypes I and II. HMA treatment drastically decreased the titers of FIPV serotype I strains Black and KU-2 in a dose-dependent manner, but it only slightly decreased the titer of FIPV serotype II strain 79-1146\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25701212'}, {'offsetInBeginSection': 1012, 'offsetInEndSection': 1206, 'text': 'In contrast, DIDS treatment decreased the titer of FIPV serotype II strain 79-1146 in dose-dependent manner, but it only slightly decreased the titers of FIPV serotype I strains Black and KU-2. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25701212'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27027316'}, {'offsetInBeginSection': 1121, 'offsetInEndSection': 1468, 'text': 'Here, we evaluated the therapeutic efficacy of our 3CLpro inhibitor in laboratory cats with FIP. Experimental FIP is 100% fatal once certain clinical and laboratory signs become apparent. We found that antiviral treatment led to full recovery of cats when treatment was started at a stage of disease that would be otherwise fatal if left untreated', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27027316'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 98, 'text': 'Therapeutic effect of anti-feline TNF-alpha monoclonal antibody for feline infectious peritonitis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26850532'}, {'offsetInBeginSection': 912, 'offsetInEndSection': 1017, 'text': 'These results strongly suggested that the anti-fTNF-alpha antibody is effective for the treatment of FIP.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26850532'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 147, 'text': 'Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32441826'}, {'offsetInBeginSection': 1515, 'offsetInEndSection': 1636, 'text': 'Treatment with GS-441524 shows clinical efficacy and may result in clearance and long-term resolution of neurological FIP', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32441826'}, {'offsetInBeginSection': 213, 'offsetInEndSection': 399, 'text': 'Mutian\u00ae Xraphconn (Mutian X) is a product marketed to treat cats with FIP but is also being used to stop virus shedding, although no clear guidelines exist for its use for this purpose. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32220667'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 84, 'text': 'Oral Mutian\u00aeX stopped faecal feline coronavirus shedding by naturally infected cats.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32220667'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 181, 'text': 'Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP).', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32521771'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'The pharmacokinetic profile of mefloquine was investigated as a preliminary study towards a potential treatment for feline coronavirus infections (such as feline infectious peritonitis) or feline calicivirus infections', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32521771'}, {'offsetInBeginSection': 918, 'offsetInEndSection': 1033, 'text': 'Mefloquine may provide a safe effective treatment for feline coronavirus and feline calicivirus infections in cats.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32521771'}, {'offsetInBeginSection': 638, 'offsetInEndSection': 816, 'text': 'In conclusion, itraconazole partly exerted a beneficial effect in a cat with FIP. However, further investigation of a possible role of itraconazole in FIP treatment is warranted.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32848107'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 126, 'text': 'Clinical efficacy of combination therapy of itraconazole and prednisolone for treating effusive feline infectious peritonitis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32848107'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 131, 'text': 'Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30755068'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 199, 'text': 'The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30755068'}, {'offsetInBeginSection': 1800, 'offsetInEndSection': 1940, 'text': 'S-441524 was shown to be a safe and effective treatment for FIP. The optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30755068'}, {'offsetInBeginSection': 280, 'offsetInEndSection': 485, 'text': 'This paper reports on the successful resolution of immunohistochemistry-confirmed effusive FIP in an adolescent cat in South Africa following monotherapy with remdesivir at 4.9-5.6 mg/kg daily for 80 days.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35934910'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 104, 'text': 'uccessful treatment of a South African cat with effusive feline infectious peritonitis with remdesivir.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35934910'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 318, 'text': 'BACKGROUND: Currently there is no drug proven to effectively treat cats with feline infectious peritonitis (FIP).HYPOTHESIS: Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival time in cats with FIP, and increase their quality of life.ANIMALS: Twenty-three privately owned cats with FIP.METHO', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22092616'}, {'offsetInBeginSection': 181, 'offsetInEndSection': 474, 'text': 'The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn\u00ae in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34835034'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 149, 'text': 'The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29778200'}, {'offsetInBeginSection': 52, 'offsetInEndSection': 202, 'text': 'fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive a', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19482534'}, {'offsetInBeginSection': 191, 'offsetInEndSection': 341, 'text': 'ed, and most of the affected cats die or are euthanized. Anecdotally, doxycycline has been used to treat FIP-affected cats, but there are currently no', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33799985'}, {'offsetInBeginSection': 1427, 'offsetInEndSection': 1577, 'text': ' and no relapse was observed.Conclusions and relevance: GS-441524 combined with GC376 can be safely and effectively used to treat FIP and reduces the ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36387398'}, {'offsetInBeginSection': 78, 'offsetInEndSection': 228, 'text': 'ritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid. A complete remission (over 2 years) and a partial', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15123155'}, {'offsetInBeginSection': 1089, 'offsetInEndSection': 1292, 'text': 'This study provides a proof of principle for the use of molnupiravir in cats and supports the need for future studies to further evaluate molnupiravir as a potentially safe and effective therapy for FIP.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36297266'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 337, 'text': 'Objectives: The main objectives of this study were to investigate the efficacy of the nucleotide analog GS-441524 in combination with the 3C-like protease inhibitor GC376 for the treatment of naturally aquired feline infectious peritonitis (FIP) and to test whether their combination shortens the dosing period and improves the cure rate', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36387398'}, {'offsetInBeginSection': 882, 'offsetInEndSection': 959, 'text': 'Our study suggested that HCQ and rfIFN-\u03c9 are applicable for treatment of FIP.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32456286'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 336, 'text': 'OBJECTIVES: The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis (FIP).METHODS: Cats ranged from 3.4-73 months of age (mean 13.6 months); 26 had effusive or dry-to-effusive FIP and five had non-effusiv', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30755068'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34835034'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 582, 'text': 'Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a common dis-ease in cats, fatal if untreated, and no effective treatment is currently legally available. The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn\u00ae in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects. Mass spectrometry and nuclear magnetic resonance identified GS-441524 as an active component of Xraphconn\u00ae.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34835034'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 394, 'text': 'Feline infectious peritonitis (FIP) is a common and highly lethal coronavirus disease of domestic cats. Recent studies of diseases caused by several RNA viruses in people and other species indicate that antiviral therapy may be effective against FIP in cats. The small molecule nucleoside analog GS-441524 is a molecular precursor to a pharmacologically active nucleoside triphosphate molecule.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29778200'}]\n\n\n                 'What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Prednisolone\", \"immune suppressive drugs\", \"glucocorticoid\", \"Cyclophosphamide\", \"Feline interferon-omega\", \"FeIFN-omega\", \"Propentofylline\", \"PPF\", \"Polyprenyl Immunostimulant\", \"GC376\", \"3C-like protease (3CLpro) inhibitors\", \"siRNA\", \"viroporin inhibitor\", \"HMA\", \"DIDS\", \"anti-feline TNF-alpha monoclonal antibody\", \"GS-441524\", \"Mutian\\u00ae\", \"Xraphconn\", \"(Mutian X)\", \"Mefloquine\", \"itraconazole\", \"remdesivir\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 543, 'offsetInEndSection': 891, 'text': 'In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781'}, {'offsetInBeginSection': 3208, 'offsetInEndSection': 3437, 'text': 'Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781'}]\n\n\n                 'What clinical applications is Zanubrutinib approved for in the United States?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"adults with mantle cell lymphoma who have received at least one prior therapy\", \"for adults with Waldenstr\\u00f6m macroglobulinemia\", \"for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'Lower grade gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p/19 codeletion) have a favorable outcome. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32894375'}, {'offsetInBeginSection': 334, 'offsetInEndSection': 568, 'text': 'diffuse glioma cases (grade 2, 56; grade 3, 62; grade 4, 182) based on this classification. Mutations in the isocitrate dehydrogenase (IDH) genes were common in lower grade glioma (LGG: grade2-3), and when combined with 1p/19q status,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34268651'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 266, 'text': 'Glioblastoma remains a deadly brain cancer with dismal prognosis. Genetic alterations, including IDH mutations, 1p19q co-deletion status and MGMT promoter methylation have been proven to be prognostic and predictive to response to treatment in gliomas. I', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34667950'}, {'offsetInBeginSection': 664, 'offsetInEndSection': 719, 'text': 'Oligodendroglioma, IDH-mutant and 1p/19q codeleted: 37;', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34268651'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': '1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32305004'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 230, 'text': 'The presence of chromosome 1p/19q co-deletion is one of the hallmark required criteria for the diagnosis of oligodendroglioma, using the 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32305004'}, {'offsetInBeginSection': 231, 'offsetInEndSection': 384, 'text': 'Descriptions in the literature of astrocytomas, primarily glioblastomas, demonstrating partial losses on one or the other chromosome have been described.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32305004'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 178, 'text': 'Oligodendroglial tumours (OT) are a heterogeneous group of gliomas. Three molecular subgroups are currently distinguished on the basis of the IDH mutation and 1p/19q co-deletion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27090007'}, {'offsetInBeginSection': 366, 'offsetInEndSection': 567, 'text': ' three subgroups within 1p/19q co-deleted tumours, associated with specific expression patterns of nervous system cell types: oligodendrocyte, oligodendrocyte precursor cell (OPC) and neuronal lineage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27090007'}, {'offsetInBeginSection': 1164, 'offsetInEndSection': 1306, 'text': 'diffuse gliomas into three distinct molecular categories: chromosome 1p/19q co-deleted/IDH mutant, intact 1p/19q/IDH mutant and IDH wild type.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29218432'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 86, 'text': 'Co-deletion of 1p/19q is a hallmark of oligodendroglioma and predicts better survival.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32681084'}, {'offsetInBeginSection': 626, 'offsetInEndSection': 794, 'text': 'The second is that examinations for IDH mutations and 1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32020379'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 140, 'text': 'Co-deletion of chromosome arms 1p and 19q, characteristic of oligodendroglial tumors, was recently found to be mediated by t(1;19)(q10;p10).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18710393'}, {'offsetInBeginSection': 1242, 'offsetInEndSection': 1382, 'text': 'These results suggest that 1p19q loss and t(1;19) occur in a subset of EVN, and may be associated with aggressive histology in these tumors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18710393'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 302, 'text': 'Background: Co-deletion of 1p and 19q marks a diffuse glioma subtype associated with relatively favorable overall survival; however, heterogeneous clinical outcomes are observed within this category.Methods: We assembled gene expression profiles and sample annotation of 374 glioma patients carrying th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28340142'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': '1p19q co-deletion is a chromosomal alteration associated with primary brain tumours of oligodendroglial histology.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25971646'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 232, 'text': 'Together with isocitrate dehydrogenase (IDH) mutation, co-deletion of 1p19q (1p19q codel) is a prerequisite for diagnosis of oligodendroglioma, making it imperative that histopathology laboratories introduce testing for 1p19q codel.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33361717'}, {'offsetInBeginSection': 141, 'offsetInEndSection': 364, 'text': 'To evaluate the prevalence of 1p19q co-deletion and t(1;19) in extraventricular neurocytomas (EVN), we studied tumors from 23 patients, including 13 females and 10 males (median age at diagnosis 34 years, range 2-76 years).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18710393'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 128, 'text': 'The IDH-mutant and 1p/19q co-deletion (1p19q codel) provides significant diagnostic and prognostic value in lower-grade gliomas.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29550880'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25277207'}, {'offsetInBeginSection': 482, 'offsetInEndSection': 654, 'text': 'Whole arm 1p19q co-deletion was present in three cases from adolescent patients and 9p loss in 3, including one low-grade oligodendroglioma with CDKN2A homozygous deletion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26206478'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'Oligodendrogliomas (ODs) are the second most common malignant brain tumor and exhibit characteristic co-deletion of chromosomal arms 1p and 19q (co-deletion 1p/19q), which is associated with down-regulation of tumor suppressors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26542540'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 195, 'text': 'Oligodendrogliomas are primary human brain tumors with a characteristic 1p/19q co-deletion of important prognostic relevance, but little is known about the pathology of this chromosomal mutation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29890994'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 312, 'text': 'It has been reported recently that oligodendroglial tumors arising in the insula rarely harbor co-deletions of chromosomes 1p and 19q, a molecular signature which is associated with a good prognosis and increased responsiveness to radiation and chemotherapy compared with tumors in which 1p and/or 19q is intact.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20035368'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 117, 'text': 'Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31157866'}, {'offsetInBeginSection': 170, 'offsetInEndSection': 286, 'text': ' We investigated a series of 1305 gliomas and showed that IDH mutation is almost constant in 1p19q codeleted tumors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24877111'}, {'offsetInBeginSection': 1197, 'offsetInEndSection': 1289, 'text': ' The study demonstrated that 1p/19q co-polysomy is a poor prognostic marker for glial tumor.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30849537'}, {'offsetInBeginSection': 209, 'offsetInEndSection': 354, 'text': ' In the brain tumor, identification of molecular alterations, including 1p/19q co-deletion, is essential for accurate glial tumor classification.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30842562'}, {'offsetInBeginSection': 1521, 'offsetInEndSection': 1658, 'text': ' In conclusion, the expression profile of 1p19q genes is highly associated with the malignancy and prognosis of 1p/19q non-codel gliomas.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31157866'}, {'offsetInBeginSection': 107, 'offsetInEndSection': 273, 'text': ' On the other hand, sequence studies have recently linked the CIC mutation and subsequent altered CIC expression to the 1p/19q co-deletion in oligodendroglial tumors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24197863'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 107, 'text': 'INTRODUCTION: Anaplastic oligodendrogliomas are high-grade gliomas defined molecularly by 1p19q co-deletion', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34125374'}, {'offsetInBeginSection': 871, 'offsetInEndSection': 1110, 'text': 'Combined immunohistochemical analysis assessed by INA expression and/or the lack of CIC expression was strongly associated with the 1p/19q co-deletion in oligodendroglial tumors, indicating a potential surrogate marker of the 1p/19q state.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24197863'}, {'offsetInBeginSection': 1342, 'offsetInEndSection': 1558, 'text': 'or purity was found to be significantly decreased in high-risk IDH-mutant with 1p/19q co-deletion gliomas and IDH-wild-type glioblastomas but not in IDH-wild-type lower grade or IDH-mutant, non-co-deleted gliomas.Con', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28340142'}, {'offsetInBeginSection': 1292, 'offsetInEndSection': 1686, 'text': 'reatment strategy. However, there are still unanswered questions regarding whether upfront chemotherapy, omitting/deferring radiotherapy, in the desire to avoid late neurocognitive toxicity of radiotherapy should be the initial therapy for AO tumors with codeleted 1p19q, or whether temozolomide, an oral agent with a better toxicity profile, can be substituted for procarbazine, lomustine, and', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23344797'}, {'offsetInBeginSection': 547, 'offsetInEndSection': 697, 'text': ' results for 1p19q co-deletions (n\\u2009=\\u20099) or EGFR amplification (n\\u2009=\\u20098). Gliomas positive for 1p19q co-deletions did not have other frequently recurrent', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26257825'}, {'offsetInBeginSection': 1462, 'offsetInEndSection': 1612, 'text': 'uation. Data concerning low-grade gliomas were more controversial. Oligodendroglial tumors with 1p deletion or 1p19q codeletion seemed to have a bette', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18565359'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'In the WHO glioma classification guidelines grade (glioblastoma versus lower-grade glioma), IDH mutation and 1p/19q co-deletion status play a central role as they are important markers for prognosis and optimal therapy planning.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33482430'}, {'offsetInBeginSection': 1214, 'offsetInEndSection': 1384, 'text': 'We confirmed the high incidence (82%) of combined 1p19q deletion in LGOs and the feasibility of successful FISH testing in paraffin embedded specimens up to 10-years-old.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19624298'}, {'offsetInBeginSection': 746, 'offsetInEndSection': 869, 'text': 'the 26 tumours, 6 oligodendrogliomas had 1p19q co-deletion and the remaining 3 oligodendrogliomas showed no co-deletion. Th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35114775'}, {'offsetInBeginSection': 158, 'offsetInEndSection': 340, 'text': 'The authors describe a case wherein a 1p19q deletion in a disseminated tumor with mixed immunohistochemical features of oligodendroglioma and neurocytoma was encountered and treated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20446099'}, {'offsetInBeginSection': 660, 'offsetInEndSection': 870, 'text': 'The lack of CIC expression was detected in 13 cases (68\\xa0%) of oligodendroglial tumors with the 1p/19q co-deletion, and in only 1 case of oligodendroglial tumors without the 1p/19q co-deletion (5\\xa0%, P\\xa0<\\xa00.0001).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24197863'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 480, 'text': '1p/19q codeletion, which leads to the abnormal expression of 1p19q genes in oligodendroglioma, is associated with chemosensitivity and favorable prognosis. Here, we aimed to explore the clinical implications of 1p19q gene expression in 1p/19q non-codel gliomas. We analyzed expression of 1p19q genes in 668 1p/19q non-codel gliomas obtained from The Cancer Genome Atlas (n = 447) and the Chinese Glioma Genome Atlas (n = 221) for training and validation, respectively. The express', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31157866'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 486, 'text': 'Oligodendroglial tumors (OTs) are primary brain tumors that show variable clinical and biological behavior. The 1p/19q codeletion is frequent in these tumors, indicating a better prognosis and/or treatment response. Recently, the prognostically favorable CpG island methylator phenotype (CIMP) in gliomas (G-CIMP+) was associated with mutations in the isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 (IDH) genes, as opposed to G-CIMP- tumors, highlighting the relevance of epi', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23689617'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 389, 'text': 'PURPOSE: Anaplastic gliomas represent a heterogeneous group of primary high-grade brain tumors, and the optimal postoperative treatment remains controversial. In this report, we present our institutional data on the clinical outcomes of radiation therapy (RT) plus temozolomide (RT + TMZ) for anaplastic gliomas, stratified by histology and 1p/19q codeletion.METHODS AND MATERIALS: A singl', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25636755'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 231, 'text': 'Oligodendroglioma (OD) is a subtype of glioma occurring in the central nervous system. The 1p/19q codeletion is a prognostic marker of OD with an isocitrate dehydrogenase (IDH) mutation and is associated with a clinically favorable', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32906679'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 187, 'text': 'Background: Co-deletion of 1p and 19q marks a diffuse glioma subtype associated with relatively favorable overall survival; however, heterogeneous clinical outcomes are observed within th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28340142'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 105, 'text': 'IDH1/2 mutations and 1p/19q codeletion occur frequently in anaplastic gliomas and are prognostic factors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23681562'}, {'offsetInBeginSection': 402, 'offsetInEndSection': 644, 'text': 'A total of 124 cases of diffuse gliomas were collected, and tissue microarray blocks were made. IDH1 mutation was tested using immunohistochemistry, and 1p/19q co-deletion status was examined using fluorescence in situ hybridization analysis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31370384'}, {'offsetInBeginSection': 5, 'offsetInEndSection': 125, 'text': ' IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective stud', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32681084'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 95, 'text': 'ultigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28340142'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 179, 'text': 'Glial tumors are malignant brain tumors that arise from glial cells of brain or spine and have genetic aberrations in their genome. 1p/19q co-deletion is associated with increased', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30849537'}, {'offsetInBeginSection': 123, 'offsetInEndSection': 312, 'text': 'We aimed to explore the expression of Olig2 in different glial neoplasms and to investigate if diffuse Olig2 expression can replace 1p19q co-deletion for the diagnosis of oligodendroglioma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35114775'}, {'offsetInBeginSection': 4, 'offsetInEndSection': 163, 'text': 'oligodendrocyte transcriptional factor-2 (Olig2) be used as an alternative for 1p/19q co-deletions to distinguish oligodendrogliomas from other glial neoplasms', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35114775'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 153, 'text': 'Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18565359'}, {'offsetInBeginSection': 366, 'offsetInEndSection': 568, 'text': 'The 1p deletions and 1p19q codeletion mean rates were respectively 65.4 and 63.3% in oligodendrogliomas, 28.7 and 21.6% in oligoastrocytomas, 13.2 and 7.5% in astrocytomas, 11.6 and 2.9% in glioblastoma', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18565359'}, {'offsetInBeginSection': 570, 'offsetInEndSection': 712, 'text': ' The presence of 1p deletion and 1p19q codeletion were strongly correlated with the histological diagnosis corresponding to oligodendroglioma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18565359'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 138, 'text': 'Losses of chromosomes 1p and 19q are deemed correlated with diagnosis of oligodendroglioma, higher chemosensitivity and better prognosis. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18565359'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 155, 'text': 'eptomeningeal dissemination of a pediatric neoplasm with 1p19q deletion showing mixed immunohistochemical features of an oligodendroglioma and neurocytoma', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20446099'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 156, 'text': 'eptomeningeal dissemination of an oligodendroglioma is rarely reported in the neurosurgical literature, especially in cases with a classical 1p19q deletion', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20446099'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 140, 'text': 'etrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19624298'}, {'offsetInBeginSection': 10, 'offsetInEndSection': 123, 'text': '1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25636755'}, {'offsetInBeginSection': 93, 'offsetInEndSection': 131, 'text': '1p/19q Codeletion in Oligodendroglioma', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32906679'}, {'offsetInBeginSection': 9, 'offsetInEndSection': 150, 'text': ' two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23681562'}]\n\n\n                 'The 1p19q co-deletion is associated with what types of tumors?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"astrocytomas\", \"glioblastoma\", \"Oligodendrogliomas\", \"oligodendrial diffuse glioma chromosome 1p/19q co-deleted/IDH mutant\", \"oligodendrocyte precursor oligodendriogial gliomas\", \"neuronal linage oligodendrogiiomas\", \"neurocytoma\"]}"}]}
